Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Fibroblast growth factor 1948 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00151 | 35208205 | Metabolites | A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver. | 2022 | Details |
| A01487 | 34727818 | Expert Opin Ther Targets | A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). | 2021 | Details |
| A01793 | 34615727 | Gut | Novel therapeutic targets for cholestatic and fatty liver disease. | 2021 | Details |
| A03364 | 34027340 | JHEP Rep | Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. | 2021 | Details |
| A03701 | 33898959 | JHEP Rep | Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. | 2021 | Details |
| A04406 | 33630750 | Eur J Endocrinol | MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases. | 2021 | Details |
| A04783 | 33506572 | Liver Int | Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease. | 2021 | Details |
| A06122 | 32998095 | Diabetes Metab Syndr | Pathophysiological mechanisms underlying MAFLD. | 2020 | Details |
| A06684 | 32781086 | Gastroenterology | Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08004 | 32282030 | Br Med Bull | Obeticholic acid-a new therapy in PBC and NASH. | 2020 | Details |
| A08065 | 32258945 | Hepatol Commun | Bile Acid Diarrhea and NAFLD: Shared Pathways for Distinct Phenotypes. | 2020 | Details |
| A08115 | 32241197 | Expert Rev Gastroenterol Hepatol | Obeticholic acid for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A08745 | 32003601 | Am J Physiol Gastrointest Liver Physiol | Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. | 2020 | Details |
| A09661 | 31655133 | J Hepatol | β-Klotho gene variation is associated with liver damage in children with NAFLD. | 2019 | Details |
| A10806 | 31181641 | J Clin Med | Bile Acid and Fibroblast Growth Factor 19 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Sleeve Gastrectomy. | 2019 | Details |
| A11551 | 30847736 | Curr Obes Rep | Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery. | 2019 | Details |
| A11649 | 30805949 | Hepatology | NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. | 2019 | Details |
| A11919 | 30682184 | PLoS One | Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. | 2019 | Details |
| A12767 | 30297626 | Int J Mol Sci | Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. | 2018 | Details |
| A12898 | 30235807 | Diseases | Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. | 2018 | Details |
| A13626 | 29866129 | BMC Gastroenterol | Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. | 2018 | Details |
| A14453 | 29404440 | Hepatol Commun | Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. | 2017 | Details |
| A15378 | 28938455 | J Clin Endocrinol Metab | Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. | 2017 | Details |
| A15671 | 28774887 | Gut | Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. | 2017 | Details |
| A15716 | 28746779 | Liver Int | Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. | 2017 | Details |
| A16193 | 28511023 | Appl Physiol Nutr Metab | Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. | 2017 | Details |
| A17857 | 27521506 | Clin Gastroenterol Hepatol | New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease. | 2016 | Details |
| A20794 | 25729888 | J Pediatr Gastroenterol Nutr | Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A20959 | 25617503 | J Hepatol | Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. | 2015 | Details |
| A21080 | 25547779 | Expert Opin Ther Targets | Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. | 2014 | Details |
| A23319 | 23873346 | Curr Opin Clin Nutr Metab Care | The gut-liver axis. | 2013 | Details |
| A23496 | 23727264 | Gastroenterology | Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. | 2013 | Details |
| A23978 | 23329754 | J Pediatr Endocrinol Metab | A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents. | 2012 | Details |
| A24822 | 22465275 | Clin Biochem | Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. | 2012 | Details |
| A30490 | 32355674 | Hepatobiliary Surg Nutr | Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease. | 2020 | Details |
| A31728 | 29973237 | J Exp Clin Cancer Res | Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. | 2018 | Details |
| A32533 | 28189755 | J Hepatol | Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. | 2017 | Details |
| A32805 | 27447573 | Oncotarget | Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. | 2016 | Details |
| A43852 | 30679232 | J Lipid Res | Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. | 2019 | Details |
| A44294 | 29119003 | BMJ Open Gastroenterol | Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis. | 2017 | Details |
| A44354 | 28865148 | Hepatology | Chronic elevation of plasma fibroblast growth factor 19 in long-term farnesoid X receptor agonist therapy, a happy marriage or cause for oncological concern? | 2017 | Details |
| A46936 | 33598648 | JHEP Rep | Gut dysbiosis as a driver in alcohol-induced liver injury. | 2020 | Details |
| A47853 | 30862680 | Diabetes | FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis. | 2019 | Details |
| A48543 | 34364916 | J Hepatol | Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver. | 2021 | Details |
| A50613 | 35325622 | Lancet Gastroenterol Hepatol | Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. | 2022 | Details |
| A50755 | 35277004 | Nutrients | Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass. | 2022 | Details |
| A52434 | 27163928 | PLoS One | Impaired Bile Acid Homeostasis in Children with Severe Acute Malnutrition. | 2016 | Details |
| A52475 | 26579439 | Acta Pharm Sin B | Bile acid nuclear receptor FXR and digestive system diseases. | 2015 | Details |